Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 19/20 | 0.65 |
| ▸ | FPR3 | P25089 | 1/20 | 0.48 |
| ▸ | GPR65 | Q8IYL9 | 1/20 | 0.48 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.48 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6835896 | 1.00 | CCR1 (0.65) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6076312 | 0.88 | CCR1 (0.73) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6838027 | 0.87 | CCR1 (0.73) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6838026 | 0.87 | CCR1 (0.73) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL6078690 | 0.85 | CCR1 (0.76) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL4587944 | 0.82 | CCR1 (0.77) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL4587955 | 0.82 | CCR1 (0.77) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL4587950 | 0.82 | CCR1 (0.77) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL4586570 | 0.82 | CCR1 (0.79) | CCR1FPR3GPR65GPR35PTGDR2 | |
| SCHEMBL4586566 | 0.82 | CCR1 (0.79) | CCR1FPR3GPR65GPR35PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058932-A1 | Novel piperazine derivatives | PFIZER INC. | 2004-03-25 | — | — | US | disclosed |
| US-6649611-B2 | Potent and selective inhibitors of chemokine binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). | PFIZER, INC. | 2003-11-18 | — | — | US | disclosed |
| EP-1268455-A2 | PIPERAZINE DERIVATIVES | Pfizer Products Inc. (US) | 2003-01-02 | — | — | EP | disclosed |
| WO-2001072728-A9 | NOVEL PIPERAZINE DERIVATIVES | PFIZER PROD INC (US) | 2002-10-10 | — | — | WO | disclosed |
| US-20020107255-A1 | Novel piperazine derivatives | PFIZER PRODUCTS INC. | 2002-08-08 | — | — | US | disclosed |
| WO-2001072728-A2 | NOVEL PIPERAZINE DERIVATIVES | PFIZER PRODUCTS INC. (US) | 2001-10-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058932-A1 | Novel piperazine derivatives | IL5, IL17A, CCR2 | CCR1 5/4885FPR3 328/4885GPR65 572/4885 |
| US-20020107255-A1 | Novel piperazine derivatives | IL5, IL17A, CCR2 | CCR1 5/4885FPR3 328/4885GPR65 572/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.